James Kuo, MD, MBA
Chief Executive Officer
Dr. James Kuo brings global life science leadership, business development and corporate finance experience to the company. He is presently Chairman of the Board at ImmunoPrecise Antibodies (TSXV: IPA) and has served as Managing Director of Athena Bioventures. He has also been Chief Executive Officer of BioMicro Systems and Discovery Laboratories (NASDAQ: DSCO). In addition, Dr. Kuo has headed business development at Myriad Genetics (NASDAQ: MYGN) and was Associate Director of Licensing and Development at Pfizer. He has further been Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy.
Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.
Dr. James Gilligan
President & Chief Science Officer
Dr. Gilligan has over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and manufacturing. Prior to joining Tryp Therapeutics, Dr. Gilligan was a Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm providing regulatory and product development support to pharmaceutical and biotech companies. Dr. Gilligan was a co-founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones, as well as oral and nasal delivery technologies for peptide based therapeutics. Dr. Gilligan was also a Co-Founder and the Chief Scientific Officer of Tarsa Therapeutics.
Dr. Gilligan received a PhD from University of Connecticut and a Masters in International Business from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.
Tom D’Orazio, B.Sc., MBA
Chief Operating Officer
Mr. D’Orazio has extensive experience leading the development and commercialization of vaccines, drugs, radiopharmaceuticals, and biologics. His leadership experience has been in commercial planning, business development, marketing and partnership management roles. Mr. D’Orazio was formerly the CEO of ImmunoPrecise Antibodies (TSXV:IPA) where he led the transition from a private company to a public company. He co-founded and led Superna Life Sciences as CEO, a specialty-pharma company focusing on niche drugs for cancer patients in Canada where he successfully in-licensed two products and succeeded in getting Health Canada approval for both drugs in head & neck cancer and prostate cancer respectively. He has commercialization experience at all stages of drug development primarily in oncology, rare diseases and ophthalmology products respectively. He held roles in business development doing both in-licensing and out-licensing as well as managing partnerships between companies and sitting on their joint development teams. At QLT he was responsible for managing their $500M/year commercial partnership with Novartis. Prior to working for QLT, Mr. D’Orazio was at Pfizer (Pharmacia U.S.A.) and managed a $250M/year portfolio that included human growth hormone where he was involved in the strategic planning for label expansion for the Prader-Willi syndrome indication.
Mr. D’Orazio has an MBA from Vanderbilt University with an emphasis in both Finance and Marketing and a B.Sc. in chemistry from Loyola University of Chicago.
Chief Financial Officer
Terese J. Gieselman has over 28 years of extensive experience with publicly listed companies listed on the CSE, TSX, TSXV, OTCBB, NASDAQ and AMEX, in the roles of Chief Financial Officer, Treasurer, and Corporate Secretary. Terese has accumulated an extensive background in corporate and financial reporting and compliance for Canada and the United States, including particularly relevant experience in financings, treasury, international corporate structures and financial reporting. Terese was previously the Chief Financial Officer for TMX-listed InMed Pharmaceuticals, a clinical stage biotech company.
Larry Norder, B.Sc.
Vice President, Manufacturing
Larry Norder has over 30 years of experience in the pharmaceutical and biotech industry. He has led chemistry aspects of early stage R&D, preclinical and clinical development programs for such products as naproxen, mycophenylate mofetil, gancyclovir, ketorolac tromethamine, nafarelin acetate, palonosetron, and topical corticosteroids. He has also been responsible for top line revenues for contract research and manufacturing, cheminformatic and bioinformatic software and associated services. Most recently, Larry has turned to the application of these set of skills to innovation and manufacturing in the nutraceuticals and natural supplements world. He has developed novel technologies to increase transdermal delivery of BCS Class II molecules, oral formulations to increase bioavailability and inhalation formulations for increased safety and efficacy. He has also developed novel methods of extraction, isolation and characterization of desirable phytochemicals.
Larry earned his BS in chemistry from the University of Illinois, a certificate in Network Software Technology Management from University of California, Santa Cruz. Larry is a member of the American Chemical Society (ACS), the American Association of Pharmaceutical Scientists (AAPS) and the International Society of Pharmaceutical Engineers (IPSE).
Peter Guzzo, PHD
Vice President, Drug Development
Dr. Guzzo has devoted his entire 25-year professional career to innovative therapeutics for poorly treated diseases. He has been involved in drug discovery, clinical research, and executive level roles. He has led cross-functional teams that delivered eleven innovative drugs into clinical development. His experience collaborating with pharma, biotech, academic institutions and contract research organizations will help us execute and push forward our drug development pipeline. Dr. Guzzo has broad knowledge in several therapeutic indications including central nervous system diseases, metabolic disorders and oncology, intellectual property creation, and building entrepreneurial teams. He is an inventor on 43 patents, co-authored 47 scientific publications, and presented 28 invited lectures.